The EU has provided much of the scientific, regulatory and trade infrastructure for the pharmaceutical industry in the UK through the European Medicines Agency (EMA). This ensures all medicines available on the EU market are safe, effective and of high quality.
Securing co-operation between the EU and UK on the regulation of medicines will be critical to providing certainty to the pharmaceutical industry in the UK and ensuring EU and UK patients are able to continue to access the medicines they need from day 1 of the UK leaving the EU.
'No deal' Brexit
The pharmaceutical industry is doing everything in its power to prepare for every Brexit outcome, including 'no deal'. Find out more about what 'no deal' means for medicines.
Our sector has worked together with government since 24 June 2016 to establish consensus on the following issues:
For the mutual benefit of patients and industry in the UK and the EU, the UK should seek to negotiate alignment and commonality with the EU for the regulation of medicines, through:
The UK should seek to negotiate continued access to long-term European funding and collaboration programmes for science, through:
The UK should seek to negotiate an agreement with the EU that facilitates the ease of movement for highly-skilled talent in Life Sciences, through:
Due to the complexity of import/export declarations and inspections, and the existing integrated nature of supply chains, the UK should seek to negotiate the ability to trade and move goods and capital across borders with the EU for pharmaceuticals and medical supplies, through:
Given the integrated nature the research, regulation and supply of medicines across Europe, The ABPI is working closely with the European Federation of Pharmaceutical Industries and Associations (EFPIA), who have established a Brexit Taskforce.
The ABPI are pleased to be a member of the NHS Confederation Brexit Health Alliance.